Clinical trial
Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes
NCT00138619 is registered in ClinicalTrials.gov with Novartis as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes
- Lead sponsor
- Novartis
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 30, 2004
- Completion date
- April 30, 2007
- Enrollment
- 478 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.